Get started

Outlook Therapeutics, Inc.

No trades
See on Supercharts
Overview
News Ideas Financials Technicals Forecast

OTLK chart

Key stats

Market capitalization
56.057MUSD
Dividends yield (FY)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.2516USD
Net income
−66.052MUSD
Revenue
—
Shares float
260.245M
Beta
0.7

About Outlook Therapeutics, Inc.

Sector
Health Technology
CEO
C. Russell Trenary
Headquarters
Iselin
Website
outlooktherapeutics.com
Employees
17
Founded
2010
ISIN
US69012T2069

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.

Ideas

OTLK Bullish Price is at the POC line (1yr) with increasing avg. daily volume since mid April. OBV is displaying bullish divergence since June as it has been increasing while the price has been decreasing. RSI is about to cross over its 13 ema. Targeting: 2.25, 2.66 Stop 2x ATR at $1.56
Long
Roadmap for OTLKBlue solid lines are established downtrends, green dotted lines are established uptrends. Both the uptrend and downtrend lines are established from equilibrium points, (not highs and lows). Thickness of lines illustrates strength of previous price action. Circles are the crossing of uptrend and down
Long
$OTLK is gonna fall todayPupm&Dump trading strategy idea. $OTLK is rising too much today. The demand for shares of the company looks lower than the supply. This and other conditions can cause a fall in the share price today. So I opened a short position from $2,89; stop-loss — $3,20; take-profit — $2,27. Do not view th
7
$OTLK good buy for long term investment$OTLK seems to be breaking out upside on the bullish news - reported statistically significant achievement on Phase 3 trial for both Primary and Secondary endpoints! The chart also shows the double bottom pattern completed with parallel channel formed above it, which is now being broken out upward
Long
OTLK Swing-trade (and potential long-term growth) ideaOTLK (Outlook Therapeutics, Inc.) is expected to commercialize the first and only FDA-approved ophthalmic formulation of bevacizumab-vikg for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan, Greater China and other markets. The stock recently spiked up in antic
Long
2
$OTLK Secures Funding to Support ONS-5010 / LYTENAVA™Outlook Therapeutics Increases Previously Announced Bought Deal Offering of Common Stock to $35.0 Million announced today that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 35,000,000 shares of co
OTLK Breakout Stock Alert Update | 174% Profit GainBREAKOUT STOCK ALERT UPDATE $OTLK - Outlook Therapeutics, Inc. - Common Stock (CV EM) Initial Alert Price: $1.32 Price High: $3.62 % Gains/Losses: 174.24% (+154.3% More Than Expected) Potential Stop Loss: $3.439 OTLK opened in today's trading session hit $3.62 in today's session without showing an
Long
OTLK Breakout Stock Alert UpdateBREAKOUT STOCK ALERT UPDATE $OTLK - Outlook Therapeutics, Inc. - Common Stock (CV EM) Initial Alert Price: $1.32 Price High: $1.65 % Gains/Losses: 25% (+5.3% More Than Expected) Potential Stop Loss: $1.5675 OTLK bounced back to the $1.65 Price Level into Today's Trading Session before meeting resi
Long
OTLK Breakout Stock Alert UpdateBREAKOUT STOCK ALERT UPDATE $OTLK - Outlook Therapeutics, Inc. - Common Stock (CV EM) Initial Alert Price: $1.32 Price High: $1.03 % Gains/Losses: -21.97% (-41.7% Less Than Expected) Potential Stop Loss: $0.9785 OTLK recently announced a $35 Million Common Stock Offering which cause the stock to d

See all ideas 

News Flow

Keep readingKeep reading

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating

An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Financials

Performance
Revenue to profit conversion
Total revenue
Gross profit
EBITDA
EBIT
Net income
‪0%‬
‪0%‬
‪0%‬
‪0%‬
‪0%‬
Debt level and coverage
Earnings
Next:—
‪0‬

Trading & brokers

Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
TradeStation
TradeStation
Featured
Stocks, Crypto, Futures
4.4Very Good
Learn more
Interactive Brokers
Interactive Brokers
Stocks, Futures, Bonds
4.3Good
Learn more

See all brokers